key: cord-0740005-xuqghktn
authors: Lim, S. H.; Campbell, N.; Johnson, M.; Joseph-Pietras, D.; Collins, G. P.; O'Callaghan, A.; Fox, C. P.; Ahearne, M.; Johnson, P. W.; Goldblatt, D.; Davies, A. J.
title: Antibody Responses after SARS-CoV-2 Vaccination in Lymphoma
date: 2021-06-12
journal: nan
DOI: 10.1101/2021.06.05.21258311
sha: 8e494ed7944085e2a6e33ff0a9e56e77f7628abf
doc_id: 740005
cord_uid: xuqghktn

Individuals with lymphoid malignancies have an increased mortality risk from COVID-19. Paradoxically, this population is least likely to be protected by SARS-CoV-2 vaccination as a result of disease- or treatment-related immunosuppression. Current data on vaccine responses in persons with lymphoid malignancies is limited. PROSECO is a UK multi-centre prospective observational study evaluating COVID-19 vaccine immune responses in individuals with lymphoma. This early interim analysis details the antibody responses to first- and second- SARS-CoV-2 vaccination with either BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca), in 129 participants. Responses are compared to those obtained in healthy volunteers. The key findings of this interim analysis are first, 61% of participants who are vaccinated during or within 6 months of receiving systemic anti-lymphoma treatment, do not have detectable antibodies despite two doses of vaccine. Second, individuals with curable disease such has Hodgkin (100%) and aggressive B-cell non-Hodgkin lymphoma (81%) develop robust antibody levels to either first or second doses, when vaccinated > 6 months after treatment completion. Third, participants incurable, indolent lymphomas have reduced antibody levels to first and second vaccine doses, irrespective of treatment history. Finally, whilst there was no difference in antibody responses between BNT162b2 and ChAdOx1 in lymphoma participants, BNT162b2 induces 11-fold higher antibody responses than ChAdOx1 after the second dose in healthy donors. These findings serve to reassure the community that individuals with treated Hodgkin and aggressive B-NHL can develop antibody responses to SARS-CoV-2 vaccine. Simultaneously it also highlights the critical need to identify an alternative strategy against COVID-19 for those undergoing systemic anti-lymphoma treatment, and for individuals with indolent lymphomas.

healthy volunteers.

The key findings of this interim analysis are first, 61% of participants who are vaccinated during or within 6 months of receiving systemic anti-lymphoma treatment, do not have detectable antibodies despite two doses of vaccine. Second, individuals with curable disease such has Hodgkin (6/6) and aggressive B-cell non-Hodgkin lymphoma (13/16) develop robust antibody levels to either first or second doses, when vaccinated > 6 months after treatment completion. Third, participants incurable, indolent lymphomas have reduced antibody levels to first and second vaccine doses, irrespective of treatment history. Finally, whilst there was no difference in antibody responses between BNT162b2 and ChAdOx1 in lymphoma participants, BNT162b2 induces 11-fold higher antibody responses than ChAdOx1 after the second dose in healthy donors.

These findings serve to reassure the community that individuals with treated Hodgkin and aggressive B-NHL can develop antibody responses to SARS-CoV-2 vaccine. Simultaneously it also highlights the critical need to identify an alternative strategy against COVID-19 for those undergoing systemic anti-lymphoma treatment, and for individuals with indolent lymphomas. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Individuals with lymphoid malignancies risk developing severe COVID-19 and are less likely to develop protective immune responses to SARS-CoV-2 vaccination because of disease-or treatmentrelated immunosuppression. Current data on vaccine responses in chronic lymphocytic leukaemia show antibody responses in 52-75% of individuals after the second dose. 1,2 Vaccine responses after two doses in persons with other lymphoid malignancies remain undefined.

In this study (NCT04858568) we report antibody levels prior to vaccination, two weeks post-first dose and/or two-four weeks post-second dose in 129 participants with lymphoma. (table S1) Participants received either ChAdOx1 (AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccines, tentwelve weeks apart. 3, 4 IgG antibodies against SARS-CoV-2 Spike antigen were measured using an electrochemiluminescent assay (MesoScale Discovery®) 5 

Antibody Units/ml (BAU/ml), calibrated against the WHO COVID-19 International Reference Serum. Antibody titres were compared to those in healthy volunteers.

Antibody titres were significantly reduced in participants "on treatment" (ongoing treatment or completed ≤ six months before vaccination) compared to "no treatment" (treatment-naive or completed therapy > six months before first vaccination).(figures 1A, S1) Post-second dose geomean titres (GMT) for both vaccines were 2·5 BAU/ml (95% CI 1·1-5·8) and 141·8 (75·6-266·0) for "on" vs. "no treatment", respectively. There was no difference in antibody levels between the vaccines within lymphoma cases despite significant differences in healthy donors (second dose; ChAdOx1 206 (124-344); BNT162b2 2339 (1923-2844), p<0.0001).

Within the "no treatment" group, participants with curable disease (100% (6/6) Hodgkin and 81% (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.05.21258311 doi: medRxiv preprint were chimeric antigen receptor T-cell recipients where 3/3 and 1/2 had no detectable antibodies after the first and second dose, respectively. Reduced antibody levels were observed in indolent B-NHL (90·2 (40·15-202·4)). This is despite treatment-naivety or completion of treatment > three years previously. In participants who completed treatment prior to vaccination, those vaccinated ≤ six months of chemotherapy +/-anti-CD20, or anti-CD20 monotherapy, and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.05.21258311 doi: medRxiv preprint with lymphoma in the "on treatment" group, blue squares represent participants with lymphoma in the "no treatment" group, and green triangles represent healthy donors. Participants "on treatment" were receiving systemic anti-lymphoma therapy at the time of administration of the first dose of vaccine, or completed treatment ≤6 months prior to the first vaccine dose, or commenced anti-systemic antilymphoma therapy <4 weeks after receiving the first vaccine dose. Participants with "no treatment" were treatment-naive or completed treatment >6 months prior to the first vaccine dose. (Median ages in years for ChAdOx1 (68;68) and BNT162b2 (70;70) in "on treatment" and "no treatment" groups, respectively; Healthy donors, median ages are 60 (range 23-70) and 43 (21-77) for ChAdOx1 and BNT162b2, respectively; No correlation was observed between anti-S levels and age for BNT162b2.)

Binding Antibody Units per ml (BAU/ml) is shown. Anti-S IgG levels ≤ 0.55 BAU/ml are below the lower limit of detection. Geometric mean titres are shown. Significance was determine using twotailed Mann-Whitney test, p<0.01(**), p<0.001(***).

(B) Anti-S IgG levels in participants with lymphoma from the "no treatment" group, after first and second doses of both vaccines are shown. Red, blue and green circles represent indolent B-NHL, aggressive B-NHL and Hodgkin lymphoma, respectively. Geometric mean titres are shown.

Significance was determine using two-tailed Mann-Whitney test, p<0.01(**). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.05.21258311 doi: medRxiv preprint

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Antibody responses after first and second Covid-19

vaccination in patients with chronic lymphocytic leukaemia. Preprints with the Lancet

Safety and Efficacy of the BNT162b2 mRNA Covid

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a singleblind, randomised, controlled, phase 2/3 trial

Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2

The PROSECO study is funded by 

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 12, 2021. ; https://doi.org/10.1101/2021.06.05.21258311 doi: medRxiv preprint